Topline data from the Phase III LITESPARK-005 study showed that Merck’s Welireg (belzutifan) met its primary endpoint of a clinically meaningful improvement in progression-free survival in patients with advanced renal cell carcinoma, the company announced Friday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,